Drug Patents: New Disclosure Rules for Drug Makers
The Senate must act next: a Senate floor vote.
This bill has strong bipartisan support and has successfully moved out of the committee stage, which is where most bills fail.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
People buying insurance on the ACA marketplace often face high out-of-pocket costs for brand-name prescriptions when generics are delayed. Reducing patent gaming could help bring cheaper alternatives to market sooner, modestly lowering drug costs for marketplace plan holders over time.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 528.
The bill is now on the schedule for the full chamber to consider. It's in line for debate and a vote.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
The committee approved this bill and is sending it to the full chamber for a vote. This is a significant step — most bills never get this far.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
The committee approved this bill and is sending it to the full chamber for a vote. This is a significant step — most bills never get this far.
Committee on Health, Education, Labor, and Pensions. Hearings held.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
No votes or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Medication Affordability and Patent Integrity Act
Analysis generated by AI. Always verify with official sources.
